Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.41 USD
-0.02 (-1.40%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $1.40 -0.01 (-0.71%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MIST 1.41 -0.02(-1.40%)
Will MIST be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MIST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIST
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
MIST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
Other News for MIST
Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
Strong Buy Rating for Milestone Pharmaceuticals Amidst Promising CARDAMYST Prospects and Market Strategy
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
Milestone Pharmaceuticals announces FDA acceptance of NDA for CARDAMYST